

# Silvio Garattini

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2410079/silvio-garattini-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

277 papers	8,856 citations	48 h-index	84 g-index
308 ext. papers	9,838 ext. citations	10.1 avg, IF	5.79 L-index

#	Paper	IF	Citations
277	How to increase value and reduce waste when research priorities are set. <i>Lancet, The</i> , <b>2014</b> , 383, 156-65	40	826
276	Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. <i>New England Journal of Medicine</i> , <b>1986</b> , 314, 1402-6	59.2	448
275	Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. <i>European Journal of Neuroscience</i> , <b>2000</b> , 12, 2623-33	3.5	378
274	Clinical pharmacokinetics of diazepam. <i>Clinical Pharmacokinetics</i> , <b>1978</b> , 3, 72-91	6.2	308
273	Prognosis of untreated patients with idiopathic membranous nephropathy. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 85-9	59.2	284
272	Caffeine disposition after oral doses. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 98-106	6.1	271
271	Non-inferiority trials are unethical because they disregard patients' interests. <i>Lancet, The</i> , <b>2007</b> , 370, 1875-7	40	151
270	Laparoscopic approach to acute abdomen from the Consensus Development Conference of the Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE), Associazione Chirurghi Ospedalieri Italiani (ACOI), Società Italiana di Chirurgia (SIC), Società Italiana di Chirurgia d'Urgenza e del Trauma (SICUT), Società Italiana di Chirurgia nell'Ospedale Privato (SICOP), and the European	5.2	150
269	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. <i>BMC Health Services Research</i> , <b>2010</b> , 10, 153	2.9	147
268	Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. <i>Journal of Comorbidity</i> , <b>2011</b> , 1, 28-44	4	132
267	Immunosuppressive effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in strains of mice with different susceptibility to induction of aryl hydrocarbon hydroxylase. <i>Toxicology and Applied Pharmacology</i> , <b>1983</b> , 68, 434-41	4.6	123
266	d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. <i>European Journal of Pharmacology</i> , <b>1986</b> , 120, 9-15	5.3	122
265	Biochemical aspects of the interaction between midbrain raphe and locus coeruleus in the rat. <i>Brain Research</i> , <b>1974</b> , 82, 178-82	3.7	118
264	1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. <i>Pharmacology</i> , <b>1986</b> , 33, 46-51	2.3	108
263	From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotonergic system and food intake. <i>Annals of the New York Academy of Sciences</i> , <b>1987</b> , 499, 156-66	6.5	104
262	Effect of etidronate disodium on the interactions between malignancy and bone. <i>American Journal of Medicine</i> , <b>1987</b> , 82, 29-33	2.4	100
261	Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>1999</b> , 18, 401-10	2.3	98

260	The serotonergic system in the brain and its possible functional connections with other aminergic systems. <i>Life Sciences</i> , <b>1975</b> , 17, 1201-9	6.8	90
259	Neurochemical mechanism of action of anorectic drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1993</b> , 73, 63-8		87
258	Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotonergic mechanisms. <i>Psychopharmacology</i> , <b>1985</b> , 85, 111-4	4.7	87
257	Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2004</b> , 28, 819-27	5.5	81
256	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. <i>Cochrane Database of Systematic Reviews</i> , <b>2014</b> , CD011230		79
255	Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1009-24	2.8	77
254	Smoking in Italy 2005-2006: effects of a comprehensive National Tobacco Regulation. <i>Preventive Medicine</i> , <b>2007</b> , 45, 198-201	4.3	73
253	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 319-36	2.2	71
252	Efficacy, safety, and cost of new anticancer drugs. <i>BMJ, The</i> , <b>2002</b> , 325, 269-71	5.9	71
251	Outrageous prices of orphan drugs: a call for collaboration. <i>Lancet, The</i> , <b>2018</b> , 392, 791-794	4.0	69
250	Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 32, 13-21	3.9	69
249	Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 504-9	8.7	67
248	Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , <b>1991</b> , 343, 483-90	3.4	67
247	The effect of nomifensine on the depletion of brain serotonin and catecholamines induced respectively by fenfluramine and 6-hydroxydopamine in rats. <i>European Journal of Pharmacology</i> , <b>1975</b> , 34, 377-80	5.3	67
246	Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMA) recommendations on the use of HR-QOL measures in drug approval. <i>Pharmacoeconomics</i> , <b>2001</b> , 19, 187-95	4.4	66
245	Approvals of drugs with uncertain benefit-risk profiles in Europe. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 572-84	3.9	63
244	Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. <i>Pharmacoeconomics</i> , <b>2008</b> , 26, 537-50	4.4	61
243	The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). <i>European Journal of Pharmacology</i> , <b>1988</b> , 151, 365-71	5.3	61

242	E-cigarette awareness, use, and harm perceptions in Italy: a national representative survey. <i>Nicotine and Tobacco Research</i> , <b>2014</b> , 16, 1541-8	4.9	60
241	Specificity of serotonergic involvement in the decrease of food intake induced by quipazine in the rat. <i>Life Sciences</i> , <b>1977</b> , 21, 1259-66	6.8	55
240	Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. <i>International Journal of Cancer</i> , <b>1980</b> , 25, 617-20	7.5	54
239	Characterization of the immunostimulants levamisole and tetramisole. <i>European Journal of Cancer</i> , <b>1975</b> , 11, 555-63		53
238	Adjusting Europe's drug regulation to public health needs. <i>Lancet, The</i> , <b>2001</b> , 358, 64-7	4.0	51
237	Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. <i>European Journal of Pharmacology</i> , <b>1988</b> , 147, 343-50	5.3	51
236	Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. <i>European Journal of Cancer</i> , <b>1981</b> , 17, 71-6		51
235	Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1992</b> , 345, 1-6	3.4	49
234	Formation of active metabolites of psychotropic drugs. An updated review of their significance. <i>Clinical Pharmacokinetics</i> , <b>1990</b> , 18, 434-59	6.2	49
233	Orphan drug development is progressing too slowly. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 355-60	3.8	48
232	Evidence that it is possible to cause anorexia by increasing release and/or directly stimulating postsynaptic serotonin receptors in the brain. <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , <b>1980</b> , 4, 363-9		48
231	Benzodiazepine receptors: correlation with pharmacological responses in living animals. <i>Life Sciences</i> , <b>1982</b> , 31, 2025-35	6.8	48
230	Uptake of 14C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. A comparative kinetic analysis. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1976</b> , 296, 59-65	3.4	47
229	Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. <i>Lancet, The</i> , <b>1982</b> , 2, 974-7	4.0	46
228	Barriers to the conduct of randomised clinical trials within all disease areas. <i>Trials</i> , <b>2017</b> , 18, 360	2.8	45
227	Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". <i>Science</i> , <b>1983</b> , 220, 517-9	33.3	45
226	Patients and the public deserve big changes in evaluation of drugs. <i>BMJ, The</i> , <b>2009</b> , 338, b1025	5.9	44
225	Walker carcinoma 256: a model for studies on tumor-induced anorexia and cachexia. <i>Oncology</i> , <b>1982</b> , 39, 173-8	3.6	43

224	Anorexia and cancer in animals and man. <i>Cancer Treatment Reviews</i> , <b>1980</b> , 7, 115-39	14.4	42
223	Biochemical hypotheses on antidepressant drugs: a guide for clinicians or a toy for pharmacologists?. <i>Psychological Medicine</i> , <b>1988</b> , 18, 287-304	6.9	40
222	Specific barriers to the conduct of randomised clinical trials on medical devices. <i>Trials</i> , <b>2017</b> , 18, 427	2.8	39
221	Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. <i>Pharmacoeconomics</i> , <b>2008</b> , 26, 91-8	4.4	39
220	Disappointing biotech. <i>BMJ, The</i> , <b>2005</b> , 331, 895-7	5.9	39
219	Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. <i>Journal of Comparative Effectiveness Research</i> , <b>2014</b> , 3, 399-422	2.1	38
218	The effect of selective lesioning of brain catecholamine-containing neurons on the activity of various anorectics in the rat. <i>European Journal of Pharmacology</i> , <b>1975</b> , 34, 373-5	5.3	38
217	The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. <i>British Journal of Pharmacology</i> , <b>1993</b> , 110, 355-9	8.6	37
216	Toxic effects of chemicals: difficulties in extrapolating data from animals to man. <i>CRC Critical Reviews in Toxicology</i> , <b>1985</b> , 16, 1-29		37
215	How can we regulate medicines better?. <i>BMJ, The</i> , <b>2007</b> , 335, 803-5	5.9	35
214	A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?. <i>Trials</i> , <b>2017</b> , 18, 556	2.8	34
213	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , <b>2015</b> , 385, 750-2	4.0	32
212	The pharmacological point of view of resistance to therapy in tumors. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 909-16	14.4	32
211	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , <b>2019</b> , 9, 2064	4.9	32
210	Letting post-marketing bridge the evidence gap: the case of orphan drugs. <i>BMJ, The</i> , <b>2016</b> , 353, i2978	5.9	31
209	Pre-market clinical evaluations of innovative high-risk medical devices in Europe. <i>International Journal of Technology Assessment in Health Care</i> , <b>2012</b> , 28, 278-84	1.8	31
208	Biological actions of drugs affecting serotonin and eating. <i>Obesity</i> , <b>1995</b> , 3 Suppl 4, 463S-470S		31
207	Evidence for covalent binding of adriamycin to rat liver microsomal proteins. <i>Biochemical Pharmacology</i> , <b>1981</b> , 30, 175-7	6	31

206	Anxiolytic activity on locus coeruleus-mediated suppression of muricidal aggression. <i>European Journal of Pharmacology</i> , <b>1984</b> , 105, 323-6	5.3	30
205	Potential by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. <i>European Journal of Pharmacology</i> , <b>1982</b> , 85, 331-3	5.3	30
204	Increase in striatal acetylcholine levels in vivo by piribedil a new dopamine receptor stimulant. <i>Life Sciences</i> , <b>1974</b> , 14, 1251-60	6.8	30
203	Older patients are still under-represented in clinical trials of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 32	9	29
202	The role of d-norfenfluramine in the indole-depleting effect of d-fenfluramine in the rat. <i>European Journal of Pharmacology</i> , <b>1993</b> , 233, 71-7	5.3	29
201	Disposition of apomorphine in rat brain areas: relationship to stereotypy. <i>European Journal of Pharmacology</i> , <b>1986</b> , 131, 229-36	5.3	28
200	A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 1791-7		27
199	Cultural shift in Italy's drug policy. <i>Lancet, The</i> , <b>1995</b> , 346, 5-6	4.0	27
198	Rare diseases: what's next?. <i>Lancet, The</i> , <b>2008</b> , 371, 1978-9	4.0	26
197	Catecholamine receptor binding in rat kidney: effect of aging. <i>Kidney International</i> , <b>1988</b> , 33, 1073-7	9.9	26
196	Different effects of fenfluramine isomers and metabolites on extracellular 5-HIAA in nucleus accumbens and hippocampus of freely moving rats. <i>European Journal of Pharmacology</i> , <b>1988</b> , 153, 295-9	5.3	26
195	Diazepam increases membrane fluidity of rat hippocampus synaptosomes. <i>FEBS Letters</i> , <b>1984</b> , 173, 255-8	3.8	26
194	Active drug metabolites. An overview of their relevance in clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1985</b> , 10, 216-27	6.2	26
193	Animal testing is still the best way to find new treatments for patients. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 39, 32-35	3.9	25
192	Serotonin and the pharmacology of eating disorders. <i>Annals of the New York Academy of Sciences</i> , <b>1989</b> , 575, 194-207; discussion 207-8	6.5	25
191	How can research ethics committees protect patients better?. <i>BMJ, The</i> , <b>2003</b> , 326, 1199-201	5.9	24
190	Most appropriate animal models to study the efficacy of statins: a systematic review. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 848-71	4.6	23
189	Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey. <i>PLoS ONE</i> , <b>2012</b> , 7, e34974	3.7	23

188	Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine. <i>European Journal of Pharmacology</i> , <b>1993</b> , 241, 255-60	5.3	23
187	In vivo stereospecific [3H]spiperone binding in rat brain: characteristics, regional distribution, kinetics and pharmacological properties. <i>European Journal of Pharmacology</i> , <b>1985</b> , 116, 63-74	5.3	23
186	Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brain. <i>European Journal of Pharmacology</i> , <b>1974</b> , 28, 214-6	5.3	23
185	New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2019</b> , 9, 522-538	4.1	22
184	A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>1996</b> , 11, 112-120	2.3	22
183	Effect of L-cysteine on the long-term depletion of brain indoles caused by p-chloroamphetamine and d-fenfluramine in rats. Relation to brain drug concentrations. <i>European Journal of Pharmacology</i> , <b>1989</b> , 163, 77-83	5.3	22
182	Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies. <i>European Journal of Pharmacology</i> , <b>1989</b> , 164, 241-8	5.3	22
181	The case of GISSI in changing the attitudes and practice of Italian cardiologists. <i>Statistics in Medicine</i> , <b>1990</b> , 9, 17-26; discussion 26-7	2.3	22
180	Effect of amphetamine and fenfluramine on brain noradrenaline and MOPEG-SO4. <i>European Journal of Pharmacology</i> , <b>1975</b> , 34, 345-50	5.3	22
179	The effect of methionine-enkephalin and D-alanine methionine-enkephalinamide on the concentration of dopamine metabolites in rat striatum. <i>European Journal of Pharmacology</i> , <b>1977</b> , 45, 207-9	5.3	22
178	Pharmacokinetics in cancer chemotherapy. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 271-82	7.5	21
177	Varying and "atypical" indications for atypical antipsychotics. <i>Psychopharmacology</i> , <b>2003</b> , 169, 205-6	4.7	21
176	Reduction of beta-adrenergic receptors by tertatolol: an additional mechanism for beta-adrenergic blockade. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 39, 245-54	6.1	21
175	Selective antimetastatic treatment--current status and future prospects. <i>Cancer Treatment Reviews</i> , <b>1974</b> , 1, 239-50	14.4	21
174	Different effects of methionine-enkephalin and (D-Ala2)methionine-enkephalin amide on the metabolism of dopamine and norepinephrine in rat brain:fact or artifact?. <i>Brain Research</i> , <b>1978</b> , 146, 392-9	3.7	21
173	Ethics in clinical research. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 792-7	13.4	20
172	Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. <i>Lancet Infectious Diseases</i> , <b>2009</b> , 9, 67-72	25.5	19
171	Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 1839-41	6	19



170	Biliary excretion of conjugated hydroxyl benzodiazepines after administration of several benzodiazepines to rats, guinea pigs, and mice. <i>Journal of Pharmaceutical Sciences</i> , <b>1972</b> , 61, 965-6	3.9	19
169	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration <b>2014</b> ,		18
168	Flaws in animal studies exploring statins and impact on meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 597-612	4.6	18
167	Fluoxetine dose and outcome in antidepressant drug trials. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 379-86	2.8	18
166	In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotonergic neuronal systems of non-human primates. A comparison with the rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1996</b> , 353, 641-7	3.4	18
165	A murine ovarian tumor with unique metastasizing capacity. <i>European Journal of Cancer</i> , <b>1981</b> , 17, 651-8		18
164	Effect of piribedil and one of its metabolites on the concentration of homovanillic acid in the rat brain. <i>European Journal of Pharmacology</i> , <b>1974</b> , 27, 245-8	5.3	18
163	Defective Fibrinolytic Response in Atherosclerotic Patients [Effect of Iloprost and Its Possible Mechanism of Action. <i>Thrombosis and Haemostasis</i> , <b>1988</b> , 60, 141-144	7	18
162	Placebo? no thanks, it might be bad for me!. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 711-4	2.8	17
161	Independent clinical research in Europe. <i>Lancet, The</i> , <b>2004</b> , 364, 1723-6	4.0	17
160	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , <b>1992</b> , 42, 981-90	9.9	17
159	Increase in rat striatal acetylcholine content by d-fenfluramine, a serotonin releaser. <i>Life Sciences</i> , <b>1979</b> , 25, 1975-81	6.8	17
158	Attitudes towards smoking regulation in Italy. <i>Lancet, The</i> , <b>2001</b> , 358, 245	4.0	16
157	Modulating the profit motive to meet needs of the less-developed world. <i>Lancet, The</i> , <b>2001</b> , 358, 1638-44	4.0	16
156	Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats. <i>European Journal of Pharmacology</i> , <b>1992</b> , 211, 137-42	5.3	16
155	Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1993</b> , 347, 306-12	3.4	16
154	Pharmacology of amineptine: synthesis and updating. <i>Clinical Neuropharmacology</i> , <b>1989</b> , 12 Suppl 2, S13-8	4	16
153	Thromboxane Synthetase Inhibition Results in Increased Platelet Sensitivity to Prostacyclin. <i>Thrombosis and Haemostasis</i> , <b>1982</b> , 47, 294-294	7	16



152	Haematological anticancer drugs in Europe: any added value at the time of approval?. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 713-9	2.8	15
151	SQ 22536, an Adenylate-Cyclase Inhibitor, Prevents the Antiplatelet Effect of Dazoxiben, a Thromboxane-Synthetase Inhibitor. <i>Thrombosis and Haemostasis</i> , <b>1984</b> , 51, 125-128	7	15
150	Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with?. <i>Trials</i> , <b>2017</b> , 18, 425	2.8	14
149	Predicting the clinical relevance of drug interactions from pre-approval studies. <i>Drug Safety</i> , <b>2009</b> , 32, 1017-39	5.1	14
148	Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. <i>European Journal of Pharmacology</i> , <b>1996</b> , 317, 369-76	5.3	14
147	Illiteracy and maternal health: educate or die. <i>Lancet, The</i> , <b>1993</b> , 341, 1063-4	4.0	14
146	Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. <i>European Journal of Pharmacology</i> , <b>1989</b> , 159, 257-64	5.3	13
145	Notes on xenobiotic metabolism. <i>Annals of the New York Academy of Sciences</i> , <b>1983</b> , 407, 1-25	6.5	13
144	New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 879-89	2.8	12
143	Disposition of D-fenfluramine in lean and obese rats. <i>Appetite</i> , <b>1988</b> , 10, 45-55	4.5	12
142	Preapproval and postapproval evidence on drugs for multiple sclerosis. <i>Neurology</i> , <b>2018</b> , 90, 964-973	6.5	11
141	EMA's reflection on placebo does not reflect patients' interests. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 877-9	2.8	11
140	Effect of two non tricyclic antidepressant drugs on [ <sup>14</sup> C]5-hydroxytryptamine uptake by rat platelets. <i>Journal of Pharmacy and Pharmacology</i> , <b>1977</b> , 29, 546-9	4.8	11
139	Provision of information on regulatory authorities' websites. <i>Internal Medicine Journal</i> , <b>2008</b> , 38, 559-67	1.6	11
138	Drugs: guide and caveats to explanatory and descriptive approaches--I. A critical evaluation of the current status of antidepressant drugs. <i>Journal of Psychiatric Research</i> , <b>1984</b> , 18, 373-90	5.2	11
137	Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 307-10	6	11
136	Differential adriamycin distribution to blood components. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1981</b> , 6, 115-22	2.7	11
135	Distribution of penfluridol in rats and mice. <i>European Journal of Pharmacology</i> , <b>1974</b> , 25, 291-5	5.3	11

134	Possible storage of (+)-amphetamine in catecholaminergic terminals of the striatum and brainstem. <i>European Journal of Pharmacology</i> , <b>1977</b> , 41, 275-9	5.3	11
133	Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,	3.7	11
132	Evaluation of benefit-risk. <i>Pharmacoeconomics</i> , <b>2010</b> , 28, 981-6	4.4	10
131	Homoeopathy: not a matter for drug-regulatory authorities. <i>Lancet, The</i> , <b>2009</b> , 374, 1578-80	4.0	10
130	European regulatory policies on medicines and public health needs. <i>European Journal of Public Health</i> , <b>2003</b> , 13, 246-51	2.1	10
129	Efficacy, safety and cost of new cardiovascular drugs: a survey. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 59, 701-6	2.8	10
128	Light and shade in proposed revision of EU drug-regulatory legislation. <i>Lancet, The</i> , <b>2003</b> , 361, 635-6	4.0	10
127	A comparative analysis of the pharmaceutical market in four European countries. <i>Pharmacoeconomics</i> , <b>1994</b> , 6, 417-23	4.4	10
126	Blockade of the diazepam-induced increase in rat striatal acetylcholine content by the specific benzodiazepine antagonists ethyl-beta-carboline-3-carboxylate and Ro 15-1788. <i>Brain Research</i> , <b>1985</b> , 336, 342-5	3.7	10
125	Influence of tumor on adriamycin concentration in blood cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1980</b> , 4, 209-12	3.5	10
124	In vitro effects of saccharin on cell-mediated host defence mechanisms. <i>Toxicology Letters</i> , <b>1980</b> , 5, 287-294	4.4	10
123	A European multi-language initiative to make the general population aware of independent clinical research: the European Communication on Research Awareness Need project. <i>Trials</i> , <b>2016</b> , 17, 19	2.8	9
122	Drug utilisation review and pharmacoeconomics: interaction after parallel development?. <i>Pharmacoeconomics</i> , <b>1993</b> , 4, 162-72	4.4	9
121	What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy?. <i>Nephron</i> , <b>1987</b> , 45, 1-6	3.3	9
120	Plasma pyroglutamic acid levels after oral administration of monosodium glutamate to human volunteers. <i>Toxicology Letters</i> , <b>1983</b> , 15, 123-9	4.4	9
119	Effects of saccharin on primary humoral antibody production in rats. <i>Toxicology Letters</i> , <b>1981</b> , 8, 1-6	4.4	9
118	Effects of physical inactivity on non-communicable diseases. <i>Lancet, The</i> , <b>2012</b> , 380, 1553; author reply 1553-4	4.0	8
117	Role of 5-HT receptors in the effect of d-fenfluramine on gastric emptying and feeding behaviour as examined in the runway test. <i>European Journal of Pharmacology</i> , <b>1991</b> , 197, 69-73	5.3	8

116	Italy ATTITUDES TO LEGISLATION ON RESTRICTION OF SMOKING. <i>Lancet, The</i> , <b>1987</b> , 329, 1310	4.0	8
115	Central Mechanisms of Fenfluramine and Related Anorectic Drugs. <i>The Japanese Journal of Pharmacology</i> , <b>1981</b> , 31, 29-35		8
114	Distribution and localization of p-hydroxy-d-amphetamine in rat brain. <i>European Journal of Pharmacology</i> , <b>1978</b> , 52, 361-5	5.3	8
113	Inconclusive messages from equivalence trials in thrombolysis. <i>Heart</i> , <b>1999</b> , 81, 675-6	5.1	8
112	Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 1735-1743	3.9	7
111	Fostering EMA's transparency policy. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 681-4	3.9	7
110	A failed attempt at collaboration. <i>BMJ, The</i> , <b>2013</b> , 347, f5354	5.9	7
109	Limits of add-on trials: antirheumatic drugs. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 33-41	2.8	7
108	CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?. <i>Psychopharmacology</i> , <b>2007</b> , 190, 265-8	4.7	7
107	Long-chain n-3 fatty acids in lipid rafts: implications for anti-inflammatory effects. <i>Journal of Cardiovascular Medicine</i> , <b>2007</b> , 8 Suppl 1, S30-3	1.9	7
106	Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach?. <i>Acta Psychiatrica Scandinavica</i> , <b>2006</b> , 113, 449-51	6.5	7
105	Clinical databases of patients receiving antidepressants. The missing link between research and practice?. <i>Journal of Affective Disorders</i> , <b>2002</b> , 70, 191-6	6.6	7
104	Efficacy, safety and cost of new drugs acting on the central nervous system. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 59, 79-84	2.8	7
103	Effects of chlorinated organics on intermediates in the heme pathway and on uroporphyrinogen decarboxylase. <i>Annals of the New York Academy of Sciences</i> , <b>1987</b> , 514, 128-40	6.5	7
102	U-46619, a stable analogue of prostaglandin H <sub>2</sub> , induces retraction of human platelet-rich plasma clots. <i>Thrombosis Research</i> , <b>1980</b> , 18, 543-5	8.2	7
101	Importance of establishing the presence of drug active metabolites. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1983</b> , 8, 97-108	2.7	7
100	The immunostimulatory activity of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazole [3,2- $\alpha$ ]-benzimidazole-2-acetic acid (NSC 208828). <i>European Journal of Cancer</i> , <b>1978</b> , 14, 393-400		7
99	Effect of cyclophosphamide on the activity and distribution of pentobarbital in rats. <i>Biochemical Pharmacology</i> , <b>1973</b> , 22, 2609-14	6	7

98	Europe's opportunity to open up drug regulation. <i>BMJ, The</i> , <b>2010</b> , 340, c1578	5.9	7
97	The European Medicines Agency is still too close to industry. <i>BMJ, The</i> , <b>2016</b> , 353, i2412	5.9	7
96	Ethics of reviewing scientific publications. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 40, 22-25	3.9	6
95	Can systematic reviews contribute to regulatory decisions?. <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 507-509	2.8	6
94	The ethics of non-inferiority trials [Authors' Reply]. <i>Lancet, The</i> , <b>2008</b> , 371, 896-897	4.0	6
93	Treatment of idiopathic membranous glomerulopathy. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1994</b> , 3, 155-63	3.5	6
92	Effect of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine on hippocampal serotonergic system, studied in freely moving rats. <i>Life Sciences</i> , <b>1990</b> , 46, 197-205	6.8	6
91	Aspirin inhibits platelet aggregation but not because it prevents thromboxane synthesis. <i>Lancet, The</i> , <b>1982</b> , 2, 775	4.0	6
90	Effect of nomifensine on acetylcholine and choline in the rat striatum and brainstem. <i>European Journal of Pharmacology</i> , <b>1976</b> , 35, 199-201	5.3	6
89	Effect of Phenobarbital on Cyclophosphamide Cytotoxic Activity and Pharmacokinetics in Mice. <i>Tumori</i> , <b>1977</b> , 63, 137-146	1.7	6
88	Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 170-174	3.8	6
87	General Practitioners and Dentists: A Call for Action Against Tobacco. <i>Nicotine and Tobacco Research</i> , <b>2016</b> , 18, 2202-2208	4.9	5
86	Trials, Regulation and tribulations. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 503-5	2.8	5
85	Reconsidering the Declaration of Helsinki. <i>Lancet, The</i> , <b>2013</b> , 382, 1247	4.0	5
84	EMA's transparency seems to be opaque. <i>Lancet, The</i> , <b>2014</b> , 384, 1847	4.0	5
83	How to improve medical information on drugs. <i>Lancet, The</i> , <b>1998</b> , 352, 151-2	4.0	5
82	Risk:benefit assessment of old medicines. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 581-6	3.8	5
81	The impact of European regulatory policies on psychotropic drug prescribing patterns. <i>International Review of Psychiatry</i> , <b>2005</b> , 17, 199-204	3.6	5

80	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , <b>1990</b> , 38, 96-100	9.9	5
79	Response of human platelets exposed to arachidonate upon stimulation with other agonists: possible role of Ca <sup>2+</sup> -i movement. <i>Biochemical and Biophysical Research Communications</i> , <b>1987</b> , 149, 1193-4	3.4	5
78	Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective. <i>Agents and Actions</i> , <b>1984</b> , 14, 109-12		5
77	Clinical evidence supporting the marketing authorization of biosimilars in Europe. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 557-566	2.8	5
76	The cultural shift in Italy's pharmaceutical policy in 1994: a case history. <i>Journal of Ambulatory Care Management</i> , <b>2004</b> , 27, 120-6	0.8	4
75	A critique to the European regulatory system. <i>Journal of Ambulatory Care Management</i> , <b>2004</b> , 27, 98-104	0.8	4
74	Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACLE (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study. <i>Angiology</i> , <b>2000</b> , 51, S3-13; discussion S14	2.1	4
73	Lack of interaction of heparin with ADP and prostacyclin on rat platelets. <i>Thrombosis Research</i> , <b>1983</b> , 31, 397-400	8.2	4
72	Rosiglitazone and the need for a new drug safety agency. <i>BMJ, The</i> , <b>2010</b> , 341, c5506	5.9	4
71	Health care: Make pharma justify the price of drugs. <i>Nature</i> , <b>2015</b> , 523, 290	50.4	3
70	Drug development: how academia, industry and authorities interact. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 602-10	14.9	3
69	Clinical trial registries: from an omen to a common and disclosed practice. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1725-6	2.8	3
68	Drug metabolism: from experiments to regulatory aspects. <i>Drug Metabolism Reviews</i> , <b>1997</b> , 29, 853-86	7	3
67	Tryptophan and depression. <i>Lancet, The</i> , <b>1997</b> , 349, 1553-4	40	3
66	The drug market in four European countries. <i>Pharmacoeconomics</i> , <b>1998</b> , 14 Suppl 1, 69-79	4.4	3
65	Confidentiality. <i>Lancet, The</i> , <b>2003</b> , 362, 1078-9	40	3
64	Ethics of testing drugs with readily available alternatives. <i>Lancet, The</i> , <b>2002</b> , 360, 647	40	3
63	Pharmaceutical prescriptions in Italy. <i>International Journal of Technology Assessment in Health Care</i> , <b>1995</b> , 11, 417-27	1.8	3

62	Perspectives in the treatment of cancer metastasis. <i>Clinical and Experimental Metastasis</i> , <b>1987</b> , 5, 105-244.7	3
61	TCDD toxicology with particular reference to Seveso: introductory remarks. <i>Drug Metabolism Reviews</i> , <b>1982</b> , 13, 345-53	7 3
60	New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable. <i>BMJ: British Medical Journal</i> , <b>2001</b> , 323, 341	3
59	Cannabis as a medicine. An update of the Italian reality. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 60, e9-e10	3.9 3
58	A disease looking for innovative drugs: The case of pulmonary arterial hypertension. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, 47-51	3.9 3
57	Italian controlled trials to assess prevention and treatment of malaria, 1900-1930s. <i>Journal of the Royal Society of Medicine</i> , <b>2019</b> , 112, 349-353	2.3 2
56	Embedding patient- and public health-oriented research in a national health service: the GISSI experience. <i>Journal of the Royal Society of Medicine</i> , <b>2019</b> , 112, 200-204	2.3 2
55	Clinical research on rare diseases of children: neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 267-273	3.5 2
54	Stamina therapies: Time to call a halt. <i>Nature</i> , <b>2014</b> , 506, 434	50.4 2
53	The European Commission should require better medicines, not just faster reimbursements. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, e1	3.9 2
52	Alternative medical practices: flashbacks from the Dark Ages. <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 245-6	3.9 2
51	Italy must invest more in science and technology. <i>Nature</i> , <b>2008</b> , 452, 685	50.4 2
50	Thrombolysis or nothing for acute myocardial infarction? It's all the same!. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 955-8	3.8 2
49	Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 707-12	2.8 2
48	Do we learn the right things from clinical trials?. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 115-25	2.8 2
47	Use of cigarette vending machines by minors in Italy. <i>International Journal of Epidemiology</i> , <b>2004</b> , 33, 432	7.8 2
46	European Council waters down European Parliament's drug-regulatory legislation. <i>Lancet, The</i> , <b>2003</b> , 362, 1688-9	40 2
45	Policing the European pharmaceutical market's priorities. <i>European Journal of Clinical Pharmacology</i> , <b>2000</b> , 56, 441-3	2.8 2

44	Antioxidant strategy for cardiovascular disease. <i>Lancet, The</i> , <b>2001</b> , 357, 1706	40	2
43	Multicentre clinical trials. <i>Lancet, The</i> , <b>1999</b> , 353, 930	40	2
42	Narcotic drug use for severe pain. <i>Lancet, The</i> , <b>1993</b> , 341, 1061-2	40	2
41	Perspectives in the field of drug metabolism. <i>Drug Metabolism Reviews</i> , <b>1994</b> , 26, 537-73	7	2
40	Pharmacology of second messengers: a critical appraisal. <i>Drug Metabolism Reviews</i> , <b>1992</b> , 24, 125-94	7	2
39	Animal use at a Milan research institute. <i>Lancet, The</i> , <b>1989</b> , 2, 1106	40	2
38	Remedies for tropical diseases. <i>Lancet, The</i> , <b>1988</b> , 1, 1338	40	2
37	The need to compare the effectiveness of the available antidepressant drugs. <i>British Journal of Psychiatry</i> , <b>1988</b> , 152, 140-1	5.4	2
36	Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides. <i>Thrombosis Research</i> , <b>1982</b> , 25, 299-306	8.2	2
35	Bevacizumab and ranibizumab. A matter of public interest. <i>BMJ, The</i> , <b>2010</b> , 341, c3721	5.9	2
34	Discrepancy remains in pharmaceutical prescriptions in four European countries. <i>BMJ: British Medical Journal</i> , <b>1998</b> , 317, 947		2
33	Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 373-375	2.8	2
32	Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 14976	4.9	2
31	The contradictions of homeopathy legislation. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 230-1	3.9	1
30	We are more than our omics. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 1043-1044	2.8	1
29	Homeopathy cannot even be used to replace placebo. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, e68	3.9	1
28	Solicited self-referencing undermines the credibility of researchers and journals. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 481-2	15.4	1
27	Antibiotics versus surgery for appendicitis. <i>Lancet, The</i> , <b>2011</b> , 378, 1067-8; author reply 1068	40	1



26	Discontinuation of Vioxx. <i>Lancet, The</i> , <b>2005</b> , 365, 24	4.0	1
25	Sparing animals and progressing in science. <i>Trends in Pharmacological Sciences</i> , <b>2003</b> , 24, 616-7	13.2	1
24	Designing the most favourable study design. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 85-6	2.8	1
23	Preliminary survey on 2,3,7,8-TCDD in cellulose-containing consumer products on the Italian market. <i>Chemosphere</i> , <b>1993</b> , 27, 1561-1564	8.4	1
22	Central side effects of pentamethylmelamine: biochemical and behavioural studies. <i>Biochemical Pharmacology</i> , <b>1984</b> , 33, 4011-5	6	1
21	Quality, efficacy, safety-it is not enough!. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 1425-1426	2.8	1
20	Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 685604	5.6	1
19	A meritorious move against homeopathy. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, e16	3.9	1
18	Brain Receptor Occupation and Kinetics of Benzodiazepine Action <b>1985</b> , 537-543		1
17	"Pharmacocentricity": from elixirs to magic bullets. <i>Lancet, The</i> , <b>1999</b> , 354 Suppl, SIV51	4.0	0
16	Macrophage-mediated cytostatic activity on tumour cells after treatment with Triton WR 1339. <i>European Journal of Cancer</i> , <b>1978</b> , 14, 229-35		0
15	Drug sales in four European countries still differ. <i>BMJ, The</i> , <b>2003</b> , 327, 1404-5	5.9	0
14	More on homeopathy. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, e20	3.9	
13	Looking for safety but overlooking efficacy: Non-inferiority trials of anti-diabetics. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 67, e9-e10	3.9	
12	Helping ethics committees separate the wheat from the chaff. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 44, e15	3.9	
11	Marketing masked as clinical research. The Phase IIIB studies and other sample cases. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 44, e16-e17	3.9	
10	Informed consent: meet patients' needs. <i>Nature</i> , <b>2012</b> , 483, 36	5.4	
9	Exenatide for type 2 diabetes. <i>Lancet, The</i> , <b>2009</b> , 373, 122; author reply 122-3	4.0	

8	Health inequalities in Italy. Collaborative Group of the Primary Prevention Project. <i>Lancet, The</i> , <b>1997</b> , 350, 1557-8	40
7	Toward new legislation on drugs in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2002</b> , 2, 51-6	2.2
6	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021071	6
5	Significance of Fenfluramine Neurotoxicity: A Kinetic Approach <b>1990</b> , 637-643	
4	Psychiatric Pharmacotherapy in Coronary Artery Disease Patients <b>2016</b> , 121-130	
3	Myth #6: Health Care Is Rightly Controlled by the Public Sector, for the Sake of Equality <b>2018</b> , 155-176	
2	Notes on the Use of Gas-Liquid Chromatography Techniques for Determination of Psychotropic Drugs in Biological Samples <b>1975</b> , 25-61	
1	Funding is not enough. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 57, e8	3.9